Technical Analysis for QURE - uniQure N.V.

Grade Last Price % Change Price Change
grade B 73.8 -1.60% -1.20
QURE closed up 0.52 percent on Tuesday, June 25, 2019, on 1.19 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical QURE trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.60%
Doji - Bullish? Reversal -1.60%
Wide Bands Range Expansion -1.60%
Overbought Stochastic Strength -1.60%
Stochastic Sell Signal Bearish -1.09%
Wide Bands Range Expansion -1.09%
Overbought Stochastic Strength -1.09%
New 52 Week Closing High Bullish -10.21%
Multiple of Ten Bullish Other -10.21%
Inside Day Range Contraction -10.21%

Older signals for QURE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
uniQure BV, a biopharmaceutical company, develops gene therapies through its modular technology platform for the treatment of genetic or acquired diseases. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency, an orphan metabolic disease. It also develops a pipeline of additional adeno-associated virus (AAV) based gene therapies, including AMT-060, a gene therapy for the treatment of hemophilia B; AMT-021 for acute intermittent porphyria; AMT-110 for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease, as well as various programs that are in early preclinical development stage. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, and University of California San Francisco. uniQure BV was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Biopharmaceutical Biology Diseases Gene Therapy Genetics Parkinson's Disease Applied Genetics Gene Delivery Treatment Of Hemophilia Adeno Associated Virus AAV Lipoprotein Lipase Deficiency Acute Intermittent Porphyria Alipogene Tiparvovec Glybera Hemophilia B
Is QURE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 82.49
52 Week Low 21.98
Average Volume 725,951
200-Day Moving Average 44.4749
50-Day Moving Average 63.7704
20-Day Moving Average 71.9125
10-Day Moving Average 76.292
Average True Range 5.073
ADX 20.91
+DI 25.8001
-DI 23.053
Chandelier Exit (Long, 3 ATRs ) 67.27099999999999
Chandelier Exit (Short, 3 ATRs ) 71.269
Upper Bollinger Band 85.8828
Lower Bollinger Band 57.9422
Percent B (%b) 0.61
BandWidth 38.853607
MACD Line 4.2181
MACD Signal Line 4.1817
MACD Histogram 0.0364
Fundamentals Value
Market Cap 1.92 Billion
Num Shares 25.6 Million
EPS -2.82
Price-to-Earnings (P/E) Ratio -26.60
Price-to-Sales 16.30
Price-to-Book 14.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 80.81
Resistance 3 (R3) 80.64 78.55 79.84
Resistance 2 (R2) 78.55 77.07 78.63 79.51
Resistance 1 (R1) 76.77 76.16 77.66 76.94 79.19
Pivot Point 74.68 74.68 75.12 74.76 74.68
Support 1 (S1) 72.90 73.20 73.79 73.07 70.81
Support 2 (S2) 70.81 72.29 70.89 70.49
Support 3 (S3) 69.03 70.81 70.16
Support 4 (S4) 69.20